YPrime’s Platform Brings Vendor-Agnostic Integration to Clinical Trial Management
MALVERN, P.A. – June 14, 2017 – YPrime announced the release of YP Connect, a cloud-based platform-as-a-service (PaaS) integration solution for clinical trials. YP Connect incorporates a real-time open architecture to directly integrate data from eClinical systems.
Designed to replace time and labor-intensive processes involved with the organization and analysis of multiple data sources collected during a clinical trial, YP Connect centralizes and transforms data into common formats across eClinical capture systems. For clinical researchers, an intuitive user interface provides reporting and a cross-platform view of their clinical trial data. YP Connect’s core features include:
- Integration ability with a broad range of data sources across legacy and modern eClinical applications.
- Robust analytical capabilities provide the ability to identify trends and anomalies in operational performance and patient-level safety data.
- Role-based reporting provides customized data views from high-level summaries to individual data points.
- The integration platform-as-a service-model (PaaS) eliminates the need for sponsor-side integration infrastructure.
“YP Connect is the first of its kind in clinical research as a vendor-agnostic clinical data integration service. It connects incompatible eClinical systems, and brings critical information together in context,” said Shawn Blackburn, YPrime CEO and co-founder. “The multiple applications used for data collection have resulted in more fragmented sources of information, and less productivity. Information organization and visualization within dashboards gives researchers the ability to make informed decisions quickly and efficiently. Our clients rely on solutions like YP Connect to bring order to the chaos of clinical trial information management.”
About YPrime
YPrime offers more than a decade of focused work with eclinical systems to expedite and improve the quality of patient management, clinical supplies, drug accountability and clinical data. Cloud-based interactive response technology (IRT) and electronic clinical outcome assessment (eCOA) platforms enable greater speed, precision and integration in clinical trial management. Our data services tools help sponsors bring together fragmented clinical research data into contextual information they can act on. YPrime’s technology and service offerings enable sponsors to move faster and more efficiently to their next development milestone.
Contact:
Katherine Cloninger
Senior Director, Marketing
kcloninger@yprime.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
